Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with 300k Patients<\/p>\n
Novo Nordisk\u2019s new oral obesity treatment is rewriting the rules of the market. Just six months after launch in the United States, the Wegovy pill has already been dispensed more than 5 million times, and its international debut is igniting a demand surge that surprised even the company\u2019s own executives. \u201cAlmost three out of 10 obesity patients on a once\u2011weekly GLP\u20111 in International Operations live in the U.K., but it\u2019s still only 1.6 million patients being treated out of 20 million. The room for market expansion is tremendous,\u201d Emil Kongsh\u00f8j Larsen, head of International Operations, told analysts after the second\u2011quarter report.<\/p>\n
The numbers bore out that optimism. In the three weeks since the pill became broadly available in early July, an estimated 300,000 patients in the U.K. started treatment, catapulting Novo Nordisk\u2019s overall U.K. obesity market share from roughly 30% to 45%. In the United Arab Emirates, where a rival oral GLP\u20111 launched a month earlier, the Wegovy pill already captured about 50% of the oral segment. The pill\u2019s momentum helped the Danish drugmaker lift its full\u2011year outlook, even as price pressures and the imminent loss of exclusivity on its legacy injectable products kept the guidance anchored in negative territory.<\/p>\n
Raising the bar despite headwinds
Novo Nordisk now expects 2026 adjusted sales and operating profit both to grow between 0% and \u20136% at constant exchange rates, an improvement from the previous forecast of a steeper decline. The upgrade was driven by better\u2011than\u2011expected GLP\u20111 product sales, particularly the Wegovy pill, which has already reached 267,000 weekly U.S. prescriptions and about 1.5 million users globally.<\/p>\n
MetricQ2 2026Q2 2025Change (CER)Adjusted salesDKK 78.5 billionDKK ~73.4 billion+7%Adjusted operating profit\u2014\u2014+11%Gross margin78.2%82.7%\u20134.5 pptsEmployees~66,700~78,700\u201315%U.S. operations sales\u2014\u2014+4%International Operations sales\u2014\u2014+10%Obesity care sales\u2014\u2014+16%GLP\u20111 diabetes sales\u2014\u2014+2%<\/p>\n
Source: Company filings. CER = constant exchange rates.<\/p>\n
CEO Mike Doustdar summed up the dichotomy: \u201cToday, Novo Nordisk is treating almost 70% more people living with obesity compared to just a year ago, with nearly five million people on our obesity treatments. \u2026 In the second quarter, we continued to invest in growth opportunities to drive competitiveness and progress our pipeline.\u201d The company poured more than DKK 26 billion into R&D and commercial activities, while simultaneously slashing headcount by 12,000 positions\u2014a 15% reduction\u2014as part of a transformation plan that is now ahead of schedule to deliver DKK 8 billion in savings by year\u2011end. Those savings are being reallocated to commercial and pipeline investments.<\/p>\n
Pill rewrites the market \u2013 and the margins
The Wegovy pill\u2019s blistering adoption is expanding the obesity category. Jamey Millar, U.S. operations chief, noted that roughly 80% of new pill patients are GLP\u20111\u2011na\u00efve, meaning the product is pulling in people who previously avoided injectable therapies. The pill has captured about 90% of the U.S. oral obesity market, with only limited cannibalisation of the injectable Wegovy. \u201cWe continue to see steady movement to the higher doses,\u201d Millar said, with about 30% of prescriptions now at the 9 mg or 25 mg strengths. A subscription model to smooth out the cost of dose escalation has attracted more than 20,000 Wegovy pill patients.<\/p>\n
Yet the rapid growth comes with a price tag. Realised prices for the injectable Wegovy plummeted, pushing U.S. injectable sales down 22% in constant currencies. CFO Karsten Munk Knudsen explained that the business mix has shifted dramatically: self\u2011pay now represents about 35% of total Wegovy injectable prescriptions, up from 10\u201115% a year ago, and those patients pay a lower net price. The overall adjusted gross margin contracted to 78.2% from 82.7%, hit by lower realised prices, a DKK 3 billion one\u2011off charge to right\u2011size manufacturing capacity agreements, and adverse currency movements. A favourable prior\u2011period rebate adjustment in the U.S. added about DKK 2 billion to the top line, however, with three\u2011quarters of that benefit coming from the diabetes drug Ozempic.<\/p>\n
International surge offsets U.S. caution
While U.S. operations grew a modest 4%, International Operations delivered 10% growth, led by the EUCAN region. Obesity care sales soared 37% outside the U.S. Emil Kongsh\u00f8j Larsen pointed to the recent launch of Wegovy 7.2 mg in a single\u2011dose pen in the U.K., and the approval in the EU with first market launches expected in Q3. Ozempic 2.0 mg, now available in around 10 countries, helped push GLP\u20111 diabetes sales in International Operations up 10%.<\/p>\n
The first generic entrants for semaglutide appeared in some early loss\u2011of\u2011exclusivity markets, but the impact has been modest so far. \u201cWe generally see the market expanding in the early LOE countries, mainly driven by more products being available at lower prices and significant promotional investments by new entrants,\u201d Larsen said. \u201cWhile the generic players have started to capture market share, we have so far been able to grow our absolute volumes.\u201d In Canada, a savings\u2011card program is retaining volumes in cash and private insurance channels as the patent expires.<\/p>\n
Pipeline: A setback, but not a derailment
The most closely watched clinical event was the failure of the ZEUS cardiovascular outcomes trial, which tested ziltivekimab, an IL\u20116 inhibitor, in patients with established cardiovascular disease, chronic kidney disease, and inflammation. The trial missed its primary endpoint with a hazard ratio of 0.99 for major adverse cardiovascular events, and showed no mortality benefit. Chief Scientific Officer Martin Holst Lange called the result disappointing but said it does not invalidate the company\u2019s cardiovascular strategy. Two other ziltivekimab trials\u2014in acute myocardial infarction and heart failure with preserved ejection fraction\u2014will continue, with readouts expected in the first half of 2027. \u201cThere is a question on the correlation between the biomarkers and the actual outcomes, and that was the leap of faith that had to be tested,\u201d Lange said. \u201cWe\u2019ve all along called out that ziltivekimab was high risk.\u201d<\/p>\n
On the more promising side, the REDEFINE 9 trial with maintenance doses of CagriSema (amylin + semaglutide) met superiority versus placebo for weight loss, and detailed data are expected later this year. A separate head\u2011to\u2011head trial against tirzepatide, REIMAGINE 4, showed CagriSema achieved 15.2% weight loss and \u20131.9% HbA1c reduction; it met non\u2011inferiority on weight but not on glucose control. Lange argued that the drug\u2019s CV risk\u2011reduction heritage from semaglutide, combined with amylin\u2019s biology, creates a compelling profile, and a high\u2011dose fixed\u2011ratio combination (2.4 mg \/ 7.2 mg) has begun Phase IIIb testing. A U.S. regulatory decision for CagriSema in obesity is expected at end\u20112026. The oral triple agonist amycretin entered Phase II with a readout due in the second half of 2027.<\/p>\n
Note: The pie chart illustrates Novo Nordisk\u2019s share jump from 30% to 45% following the Wegovy pill introduction, based on IQVIA sell\u2011in data shared on the call. Other shares are approximate.<\/p>\n
Guidance and the road to 2027
Management repeatedly stressed that the improved outlook for the full year must be viewed against a challenging second\u2011half setup. Karsten Knudsen broke down the headwinds: the loss of exclusivity for oral semaglutide in Canada and Brazil, which began hitting in the second half, and the absence of a DKK 5 billion gross\u2011to\u2011net benefit that flattered the third and fourth quarters of 2025. \u201cThat comparative effect we don\u2019t carry forward into next year, whilst the loss of exclusivity impact will annualize into next year,\u201d Knudsen said.<\/p>\n
Analysts pressed for hints on 2027. Knudsen declined to give specifics, but noted the company delivered 7% growth this quarter, and pointed to potential catalysts like CagriSema\u2019s obesity decision, the U.S. regulatory decision on oral semaglutide 25 mg for diabetes, and the annualisation of patent expiries. \u201cDon\u2019t count us out yet,\u201d he said. CEO Doustdar added that any transformative M&A is not on the immediate horizon: \u201cI\u2019m a person who never starts with a no. One day, maybe, but you have to be in a very different situation than Novo Nordisk is today. \u2026 Today, we are trying to bolt on to what Martin is doing in various areas.\u201d<\/p>\n
In the Q&A, James Quigley of Goldman Sachs asked about the comparability of the U.K. and U.S. Wegovy pill trajectories. Emil Kongsh\u00f8j Larsen acknowledged a pent\u2011up demand effect in the U.K. but noted the injection barrier is \u201cvery real\u201d and that the market\u2019s low treatment penetration points to sustained uptake. For Germany, where the pill launches in September and telehealth already drives more than half of new prescriptions, the company is \u201cbullish.\u201d Jamey Millar said the Medicare Part D Bridge program, which started on 1 July, is seeing strong participation and smooth patient navigation, though it remains early to assess durability.<\/p>\n
Novo Nordisk enters the second half of 2026 with a rare combination: a blockbuster pill that is expanding the obesity market at breakneck speed, a leaner cost structure, and a pipeline that is advancing\u2014but also the looming reality of generic erosion and constant pricing battles that keep a lid on the bottom line. The Capital Markets Day scheduled for September may provide a more detailed long\u2011term playbook. For now, investors are betting that the pill\u2019s momentum, and the promise of CagriSema, can carry the company through its most turbulent transition in decades.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with…\n","protected":false},"author":2,"featured_media":140874,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[14738,50907,3335,2835,4239,2833,35639,67506,2832,272,3102,67505,294,1910,66805],"class_list":["post-140873","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cagrisema","tag-emil-kongshoj-larsen","tag-glp-1","tag-international-operations","tag-jamey-millar","tag-karsten-munk-knudsen","tag-martin-holst-lange","tag-medicare-part-d-bridge","tag-mike-doustdar","tag-novo-nordisk","tag-ozempic","tag-u-s-operations","tag-united-kingdom","tag-wegovy","tag-ziltivekimab"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117043499212955964","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/140873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=140873"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/140873\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/140874"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=140873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=140873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=140873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}